Wells Fargo reiterated coverage on Turning Point with a new price target
$TPTX
Biotechnology: Pharmaceutical Preparations
Health Care
Wells Fargo reiterated coverage of Turning Point with a rating of Overweight and set a new price target of $85.00 from $120.00 previously